# Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC

> **NCT07549100** · — · RECRUITING · sponsor: **Shandong Provincial Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Locally Advanced Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab Plus Chemotherapy

## Key facts

- **NCT ID:** NCT07549100
- **Lead sponsor:** Shandong Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07549100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07549100, "Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07549100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*